Acción NXEN NEXIEN BIOPHARMA, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Nexien BioPharma, Inc.

Acciones

NXEN

US65343D1000

Mercado cerrado - OTC Markets
Otros sitios de cotización
 21:17:42 28/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0187 USD +14,02 % Gráfico intradía de Nexien BioPharma, Inc. +14,72 % -27,80 %
15/05 Nexien BioPharma, Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 31 de marzo de 2024 CI
20/02 Nexien BioPharma, Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021
NEXIEN BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Nexien BioPharma, Inc. announced that it has received $0.15 million in funding from Quick Capital, LLC
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NXEN
  4. Noticias Nexien BioPharma, Inc.
  5. Otros idiomas
-40% Oferta por Tiempo Limitado: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA